These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 2149460

  • 1. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
    Schröder FH.
    Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460
    [Abstract] [Full Text] [Related]

  • 2. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
    Pavone-Macaluso M, Serretta V, Pavone C, Romano C, Daricello G.
    Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The place and the results of monotherapy.
    Bonnet P.
    Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120
    [No Abstract] [Full Text] [Related]

  • 5. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R, Pahalajani G, Agarwal A, Zippe C.
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [Abstract] [Full Text] [Related]

  • 6. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
    Mahler C, Verhelst J, Denis L.
    Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    Migliari R, Muscas G, Murru M, Verdacchi T, De Benedetto G, De Angelis M.
    Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
    [Abstract] [Full Text] [Related]

  • 9. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
    Furr BJ.
    Horm Res; 1989 Dec; 32 Suppl 1():69-76. PubMed ID: 2533159
    [Abstract] [Full Text] [Related]

  • 10. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
    Kennealey GT, Furr BJ.
    Urol Clin North Am; 1991 Feb; 18(1):99-110. PubMed ID: 1992575
    [Abstract] [Full Text] [Related]

  • 11. [Antiandrogen in prostate cancer].
    Maeda O, Usami M.
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract] [Full Text] [Related]

  • 12. Antiandrogens as monotherapy for prostate cancer.
    Schröder FH.
    Eur Urol; 1998 Dec; 34 Suppl 3():12-7. PubMed ID: 9854190
    [Abstract] [Full Text] [Related]

  • 13. Nilutamide: an antiandrogen for the treatment of prostate cancer.
    Dole EJ, Holdsworth MT.
    Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
    [Abstract] [Full Text] [Related]

  • 14. Monotherapy in advanced prostate cancer: an overview.
    Baltogiannis D, Giannakopoulos X, Charalabopoulos K, Sofikitis N.
    Exp Oncol; 2004 Sep; 26(3):185-91. PubMed ID: 15494685
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
    Akakura K, Furuya Y, Ito H.
    Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
    [Abstract] [Full Text] [Related]

  • 17. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 18. [Indications of antiandrogens in benign hyperplasia of the prostate].
    Benassayag E.
    J Urol (Paris); 1995 Sep; 101(2):109-10. PubMed ID: 8522854
    [No Abstract] [Full Text] [Related]

  • 19. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer.
    Habenicht UF, Schröder H, el Etreby MF, Neumann F.
    Prog Clin Biol Res; 1988 Sep; 260():63-75. PubMed ID: 2966407
    [No Abstract] [Full Text] [Related]

  • 20. Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
    Pavone-Macaluso M, Serretta V, Daricello G, Pavone C, Cacciatore M, Romano C, Cavallo N.
    Prog Clin Biol Res; 1990 Sep; 350():149-57. PubMed ID: 2201041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.